LOGIN-VSI
29.7.2020 14:32:11 CEST | Business Wire | Press release
HTG – Howell Technology Group, the specialised supplier of innovative IT and security solutions, today announced that it has signed a supplier agreement with Login VSI , the company dedicated to maximising the end-user experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200729005078/en/
Delivered through a customer-centric approach, HTG’s professional and trusted IT consulting services enables customers to operate sustainably and achieve efficiencies gained from transformation of their IT environments to modern, cloud-based workspaces.
This partnership will focus on the provision of specialist solutions and services as part of the ecosystem for Windows Virtual Desktop (WVD). Working closely with Microsoft as a Gold partner, HTG is already deploying WVD to some impressive accounts as a cloud-based, remote working solution. Adding Login VSI to this mix represents an opportunity for HTG to join forces with the market leader in synthetic user testing.
Kevin Howell, CTO, HTG said, “Sizing end-user compute solutions to deliver optimal user experience and performance can be complex. Using Login VSI allows us to deliver our services in a performant and efficient manner.”
For Login VSI, this partnership represents the opportunity to work with a highly regarded consultant. Using their specialised skills, HTG will be able to efficiently deploy Login Enterprise into their customer base – delivering to them application compatibility testing, load testing, as well as performance and availability testing in a single platform.
Since the onset of COVID, there has been an increased demand for enterprise IT organisations to support a global remote working model. Testing of a scaled-up remote infrastructure has therefore become critical. Login VSI provides comprehensive testing and validation of the entire technology stack, from the core to the endpoint. It maximises the scalability and availability of applications and virtual desktop environments, including cloud. Login Enterprise, Login VSI’s flagship product, enables enterprises to quickly identify potential performance or availability issues by measuring and comparing application load times and application responsiveness. It is this expertise that will provide added value to HTG’s services within the digital workspace and especially as part of the WVD ecosystem.
Graham Wight, CEO, HTG commented: “We are excited about the opportunity to work with Login VSI. With the recent shift in demand for technologies that enable the smooth and secure transition to remote working, there is a greater need for performance and availability testing. The addition of this service under the partnership can only enhance and add value to the services we provide our customers.”
“We are excited about the opportunity to work with HTG,” said Eric-Jan van Leeuwen, CEO of Login VSI. “Given the global shift to remote working, there is a greater need for performance and availability testing, in order to ensure business continuity. With HTG’s superior knowledge of the WVD market and the unrivalled experience they have, we believe this is the beginning of a long-lasting relationship.”
About HTG
HTG is a leading global IT solutions company offering a range of disruptive technologies and best in class products. We work closely with customers from a wide range of industries to enable efficiencies through transformation of their IT environments and help simplify the way our IT services are delivered to them. Our digital knowledge and expertise in the latest technologies enables us to help our customers define their digital vision and strategic roadmap, delivering real and impactful change.
For further information please visit www.htguk.com or contact us on 0191 481 3446 .
About Login VSI
Login VSI is the only solution in the market guaranteed to maximize the end-user experience for digital workspaces. We reduce risk and ensure business continuity by safeguarding application and desktop performance. We do this using synthetic users to automatically test and validate the impact of change in physical, virtual and cloud-based workspaces.
Our flagship product, Login Enterprise integrates application compatibility testing, load testing, as well as performance & availability testing into a single platform. Login Enterprise also includes standard “out-of-the-box” application template workloads. Login VSI has over 400 customers in 50 countries. For more information, visit www.loginvsi.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200729005078/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom